Management of Acute Poisoning in the Intensive Care Unit
Published on 24 Jul 2024 · Updated 15 Nov 2026
Published on 24 Jul 2024 · Updated 15 Nov 2026
https://medicaltoxic.com/guidelines/acute-poisoning-icu-management
Assessment, stabilization, targeted treatment, and escalation of care
Author: Omid Mehrpour, MD, FACMT
Last revised: November 13, 2026
Primary audience: Emergency physicians, intensivists, medical toxicologists, clinical toxicologists, and poison-center clinicians.
Scope: Primarily adult acute poisoning; apply pediatric-, pregnancy-, and condition-specific protocols when relevant.
Severe poisoning can cause respiratory failure, seizures, dysrhythmias, shock, metabolic derangements, and delayed organ injury. Management begins with physiologic stabilization, a working toxicologic diagnosis, targeted interventions, repeated reassessment, and timely escalation. Initial clinical stability may be deceptive, particularly after modified-release ingestion or exposure to substances with toxic metabolites. [1], [2]
This evidence-informed clinical review is not a standing order set, a substitute for bedside judgment, or a complete antidote-dosing manual. Follow current institutional protocols for doses, infusions, monitoring, contraindications, and local availability. Obtain early medical-toxicology or poison-center input for severe or uncertain cases.
In the United States, Poison Control: 1-800-222-1222.
Do not delay resuscitation while seeking consultation.
Clinical warning
Severe poisoning may deteriorate after an initially reassuring examination. Prioritize airway, ventilation, circulation, bedside glucose, ECG, and poison-center consultation. Do not delay resuscitation for toxicology screens. In suspected salicylate poisoning, intubation can worsen toxicity if compensatory hyperventilation is lost. Avoid empiric flumazenil in mixed or uncertain overdose. Antidotes, activated charcoal, and extracorporeal treatment require poison-specific indications, contraindication assessment, and ongoing monitoring. EXTRIP thresholds are agent- and formula-specific; methanol and ethylene glycol use different anion-gap calculations. Seek early nephrology, ECMO, or transplant consultation when severe poisoning warrants it. This guideline is not a standing order set.
Priority | Immediate action | High-risk exception or escalation |
|---|---|---|
Prevent secondary exposure | Use appropriate PPE; remove contaminated clothing and decontaminate when needed. | Coordinate hazardous-material precautions with resuscitation. |
Airway and ventilation | Assess ventilatory effort, protective reflexes, and trajectory; oxygenate and assist ventilation as indicated. | In salicylate poisoning, avoid abrupt loss of compensatory hyperventilation during intubation. |
Circulation | IV/IO access, ECG, perfusion assessment, judicious fluids, vasopressors for persistent shock. | Obtain early echocardiography in suspected cardiogenic/vasodilatory toxin-induced shock. |
Immediately reversible causes | Check bedside glucose; treat hypoglycemia. Titrate naloxone when opioid-induced respiratory depression is suspected. | Target adequate ventilation, not necessarily wakefulness. Avoid a routine “coma cocktail.” |
ECG and focused tests | Obtain a 12-lead ECG and appropriate glucose, electrolytes, blood gas, lactate, and targeted toxicant studies. | Serial ECGs; a normal early ECG does not eliminate delayed-release risk. |
Mobilize expertise | Contact poison center/toxicologist; request nephrology, ECMO, or transplant input early when indicated. | Transfer before deterioration when antidotes or advanced organ support are unavailable. |
Source note: This table summarizes stabilization and risk-assessment principles, rather than supplying independent standing orders. See AHA 2025 [1] and a clinical poisoning review [2].
Severe poisoning may cause respiratory failure, seizures, dysrhythmias, shock, metabolic derangements, and delayed organ injury. Management is anchored in physiologic stabilization, a working toxicologic diagnosis, targeted interventions, repeated reassessment, and timely escalation.
Clinical deterioration may occur after an initially reassuring presentation, particularly with modified-release formulations or toxic metabolites. [1]
This document retains the grading of the cited organization rather than inventing a new GRADE rating.
AHA COR/LOE: Class of Recommendation and Level of Evidence, reported when material.
EXTRIP 1D: Strong recommendation supported by very-low-quality evidence.
EXTRIP 2D: Weaker recommendation supported by very-low-quality evidence.
CTRC: Strong or weak recommendations use that group's own grading system.
Practice point: Pragmatic clinical interpretation, not an independently graded recommendation.
The words recommended and suggested in the EXTRIP tables reproduce the original workgroup terminology. They must not be interpreted as evidence of high-quality randomized clinical trials. [1], [3], [8], [16]
This is a targeted narrative clinical review, not a new systematic review, consensus-development exercise, or locally validated ICU protocol.
Evidence is often observational or based on pharmacology, case series, and expert consensus.
Bedside dosing requires an approved poison-specific protocol.
Protect staff from gases, chemical residues, volatile substances, or contaminated clothing.
Arrange decontamination when necessary while continuing critical stabilization.
Assess:
Respiratory effort
Airway reflexes
Oxygenation
Ventilation
Clinical trajectory
Intubate for failure of ventilation or oxygenation, inability to protect the airway, refractory seizures, or anticipated deterioration.
Use clinical assessment rather than an isolated Glasgow Coma Scale cutoff.
Practice point — ungraded.
In salicylate poisoning, preserve compensatory minute ventilation and pH before, during, and after airway management. Intubation may rapidly worsen acidemia and central nervous system toxicity. [2], [4]
Obtain IV/IO access.
Monitor:
ECG
Blood pressure
Oxygen saturation
Mental status
Urine output
Consider fluid boluses only when appropriate, followed by vasopressors for persistent shock.
Bedside echocardiography helps distinguish cardiogenic from vasoplegic shock. [22]
Measure point-of-care glucose and promptly treat hypoglycemia.
For suspected opioid-related respiratory depression, assist ventilation and titrate naloxone to adequate breathing. [1]
Consider parenteral thiamine when deficiency risk is significant, including:
Malnutrition
Chronic heavy alcohol use
Bariatric surgery
Hyperemesis
Prolonged poor intake
Give thiamine concurrently with or promptly after glucose.
Do not withhold glucose from a hypoglycemic patient to give thiamine first. [5], [6]
Obtain an early 12-lead ECG and repeat as clinical conditions change.
Seek poison-center or medical-toxicology advice for:
High-risk agents
Poorly characterized combinations
Difficult antidote decisions
Organ-support escalation
Practice point: Do not administer a routine undifferentiated “coma cocktail.”
Dextrose is directed at hypoglycemia or justified empiric rescue if testing is immediately unavailable.
Naloxone is directed at clinically suspected opioid-induced ventilatory failure.
Reserve flumazenil for selected low-seizure-risk cases after individualized evaluation; avoid routine use in mixed or unknown overdose. [1], [2]
Document:
Agent and formulation
Dose range, including maximum possible dose
Exposure route and time window
Intent
Co-ingestants
Chronic use
Renal and hepatic function
Relevant pregnancy status
Treatments already given
Cross-check EMS information, medication bottles, pharmacy histories, and collateral reports.
State what is uncertain. An unreliable dose or exposure time should not be converted into a falsely reassuring estimate.
Clinical pattern | Recognizable features | Important caveat |
|---|---|---|
Opioid-like | CNS depression, bradypnea, often miosis | Clonidine and guanfacine can mimic opioids without being opioids. |
Sedative-hypnotic | Sedation, ataxia, hypoventilation with severe or mixed poisoning | Unexpected profound respiratory failure should prompt a co-exposure search. |
Sympathomimetic | Agitation, diaphoresis, mydriasis, tachycardia, hyperthermia | Treat hyperthermia and seizures before waiting for assays. |
Antimuscarinic | Delirium, dry or flushed skin, mydriasis, tachycardia, urinary retention | Diphenhydramine and tricyclics may also block sodium channels. |
Cholinergic | Bronchorrhea, bronchospasm, fasciculations, weakness, secretions | Respiratory secretions and neuromuscular failure dictate early treatment. |
Serotonin toxicity | Clonus, hyperreflexia, diaphoresis, agitation, hyperthermia | Severe rigidity and hyperthermia are emergencies; an antidote is not the first priority. |
Source note: These are clinical recognition aids adapted from general acute poisoning assessment. Co-ingestions, mimics, and evolving physiology can invalidate a pattern. [2]
Obtain bedside glucose and serial ECGs in significant or unidentified poisoning.
Select additional investigations according to the presentation:
Electrolytes and bicarbonate
Creatinine
Magnesium and calcium
Blood gas and lactate
Liver tests
Creatine kinase
Coagulation tests
Pregnancy testing
In suspected intentional or mixed exposure, consider a timely acetaminophen concentration. [7]
Order serial salicylate concentrations when relevant. [4], [8]
Target drug assays to decisions that change management, including:
If carbon monoxide poisoning or methemoglobinemia is suspected, request laboratory co-oximetry rather than relying on routine pulse oximetry. [13], [14]
Practice point: Confirm with the laboratory which specimen types its co-oximetry panel is validated for and its known interferences. Performance is not interchangeable across platforms.
Interpret both QRS and QTc.
QRS widening and terminal rightward forces in aVR can support sodium-channel blockade.
QTc prolongation alone is not an indication for sodium bicarbonate.
Repeat ECGs during ongoing absorption or changing perfusion. [1]
Interpret the anion gap using the local laboratory reference interval and adjust for hypoalbuminemia when relevant.
A value within the laboratory's reference interval does not exclude early toxic alcohol exposure or another clinically important disorder.
Serial acid–base trends and exposure history matter.
A commonly used formula is:
AG = Na − (Cl + HCO₃)
However, EXTRIP uses different formulas for different toxic alcohols:
Poison | EXTRIP anion-gap formula |
|---|---|
Methanol | Na − Cl − HCO₃ |
Ethylene glycol | Na + K − Cl − HCO₃ |
Do not transfer numerical cutoffs between these formulas. [2], [15], [16]
Osmol gap is measured minus calculated osmolality, with ethanol appropriately included.
An elevated osmol gap is nonspecific and can reflect:
Isopropanol
Ketoacidosis
Propylene glycol
Other osmotically active substances
A normal osmol gap does not exclude methanol or ethylene glycol poisoning, particularly late after parent alcohol metabolism.
Isopropanol typically causes ketosis and osmol-gap elevation without the high-anion-gap metabolic acidosis characteristic of methanol or ethylene glycol, although concurrent illness can produce acidosis. [15], [16], [17]
Urine immunoassays are presumptive.
They may miss synthetic opioids and novel psychoactive substances and may remain positive from prior exposure.
Do not use a negative routine screen to exclude clinically important poisoning or delay treatment.
Discuss targeted mass spectrometry with the laboratory when its result could change management. [18]
Practice point: Target imaging to clinical indications:
Chest imaging for suspected aspiration or pulmonary complications
Neuroimaging for trauma, focal findings, or alternative diagnoses
Abdominal imaging for suspected internal drug packets or radiopaque material
Abdominal radiography has limited sensitivity for drug packets.
In a comparative study against low-dose CT, radiography detected packets in 41 of 53 carriers, corresponding to sensitivity 0.77 and specificity 0.96.
False negatives were associated with packets isoattenuated to bowel contents and with fewer than 12 packets.
A negative abdominal radiograph therefore does not exclude body packing. [20]
Do not assume modified-release products are radiopaque.
Image selection must be exposure- and patient-specific. [2], [19]
Individualize activated-charcoal use according to:
Toxin
Potentially toxic quantity
Formulation
Time since ingestion
Expected adsorption
Aspiration risk
The traditional one-hour window is not absolute.
The 2026 Clinical Toxicology Recommendations Collaborative (CTRC) supports selected poison-specific use up to six hours and, when substantial gastrointestinal absorption is credibly continuing, sometimes later.
This is not a universal six-hour charcoal rule. [3]
The CTRC found no routine role for activated charcoal in poisoning with:
Arsenic
Caesium
Copper
Ethanol
Methanol
Ethylene glycol
Iron
Lead
Lithium
Metformin
For metformin specifically, the guidance:
Suggests against single-dose or additional-dose activated charcoal (2D)
Recommends against multiple-dose activated charcoal (1D)
These recommendations must not be misrepresented as equally strong prohibitions for every conceivable exposure.
Evaluate mixed exposures independently.
Thallium is a clinically important exception among metals, with a role for charcoal in selected cases. [3]
Intervention | Purpose | Selected circumstances |
|---|---|---|
Single-dose activated charcoal | Initial gastrointestinal binding | Agent-, dose-, formulation-, and time-specific |
Additional-dose activated charcoal | Complete gastrointestinal decontamination when substantial unabsorbed toxin may persist | Selected acetaminophen, carbamazepine, paraquat, phenobarbital, salicylate, thallium, theophylline, valproate, and verapamil exposures |
Multiple-dose activated charcoal (MDAC) | Enhanced elimination | Selected carbamazepine, cardiac glycoside, colchicine, dapsone, phenobarbital, phenytoin, thallium, and theophylline poisoning |
These are distinct interventions and must not be used interchangeably.
Source recommendations remain specific to the agent, dose, formulation, timing, and clinical context.
Protect the airway and monitor bowel function. [3]
Do not administer activated charcoal to a patient with absent or imminently lost protective airway reflexes unless the airway is safely secured.
Do not routinely intubate solely to administer charcoal.
However, in a very large, potentially life-threatening ingestion with few alternative treatments, intubation specifically to permit activated charcoal may be reasonable after individualized expert assessment.
For patients already requiring intubation for clinical reasons, NG/OG administration may be reasonable.
CTRC discourages placing an NG/OG tube in an unintubated patient solely to administer activated charcoal.
Assess:
Perforation risk
Ileus or obstruction
Aspiration risk
Possible urgent endoscopy
Consider whole-bowel irrigation (WBI) only with specialist input for selected:
Substantial sustained-release or enteric-coated ingestions
Iron, lithium, or potassium ingestions
Body packing
The standing 2015 position paper reviewed literature through February 2013 and found no convincing clinical evidence that WBI improves outcomes.
Avoid WBI in:
Bowel obstruction
Ileus
Perforation
Hemodynamic instability
Unprotected airway
Practice point: Suspected drug-packet rupture with abrupt severe toxicity is a resuscitation and urgent surgical/toxicology emergency—not simply an indication to continue WBI.
Do not routinely induce emesis or perform gastric lavage. Assess rare exceptional indications with medical-toxicology consultation. [2]
Provide ventilation and airway support as needed.
Titrate naloxone to adequate respiration.
Repeat dosing or infusion may be necessary after reversal of long-acting opioids.
Observe for recurrent toxicity and aspiration.
Flumazenil is not an antidote for undifferentiated coma and should not be used empirically in mixed overdose. [1]
Determine the agent, formulation, co-ingestants, and shock phenotype.
Begin with perfusion assessment, appropriately limited fluids, and vasopressors.
For life-threatening hypotension caused by calcium channel blocker (CCB) poisoning, the AHA recommends:
High-dose insulin: COR 1, LOE B-NR
Vasopressors: COR 1, LOE C-LD
IV calcium: Reasonable, COR 2a, LOE C-EO
The adult CCB consensus similarly identifies calcium, high-dose insulin, and norepinephrine/epinephrine as first-line choices while acknowledging very-low-quality evidence. [1], [22]
For life-threatening beta-blocker toxicity, AHA recommendations include:
Vasopressors: COR 1, LOE C-EO
High-dose insulin for hypotension refractory to vasopressors: COR 1, LOE C-LD
Glucagon bolus followed by infusion for symptomatic bradycardia or hypotension: Reasonable, COR 2a, LOE C-LD
Glucagon's usefulness in CCB poisoning remains uncertain. [1]
High-dose insulin euglycemia therapy (HIET) requires:
A validated institutional dosing and titration protocol
Frequent glucose and potassium monitoring
Dextrose replacement
Fluid-balance review
Reassessment of contractility and perfusion
Treat insulin-related potassium shifts carefully rather than automatically replacing every modest decrease.
Consider early VA-ECMO referral for refractory cardiogenic shock when an experienced service is available. [1], [22]
For the poison-specific pathway, see Calcium Channel Blocker Poisoning: High-Dose Insulin, Vasopressors, Calcium, and VA-ECMO.
Suspect sodium-channel blocker cardiotoxicity when QRS widening, aVR abnormalities, ventricular dysrhythmia, seizures, or shock occur after exposure to agents such as:
Tricyclic antidepressants
Diphenhydramine
Certain antiarrhythmics
Other sodium-channel-blocking substances
IV sodium bicarbonate is indicated for life-threatening cardiotoxicity from tricyclic or tetracyclic antidepressants (AHA COR 1, B-NR).
It is also reasonable for other life-threatening sodium-channel blocker poisoning (COR 2a, C-EO).
Monitor:
QRS response
Serum sodium
pH
Potassium
Ventilation
Avoid excessive alkalemia.
QT prolongation alone does not justify sodium bicarbonate.
Treat torsades de pointes according to established dysrhythmia protocols, including magnesium, correction of electrolytes, and expert-directed rate management when appropriate.
Refractory poisoning requires early medical-toxicology and ECMO discussion. [1]
Obtain serial salicylate concentrations together with neurologic, respiratory, pH, and renal assessment.
Falling serum salicylate concentrations do not establish improvement when acidemia or CNS toxicity is progressing.
For significant poisoning:
Use IV bicarbonate-based urine alkalinization.
Commonly target urine pH 7.5–8.0.
Maintain adequate potassium and urine output.
Monitor serum pH, volume status, and electrolytes.
Avoid acidemia during intubation.
Severe poisoning may require hemodialysis irrespective of a single serum concentration.
Continue bicarbonate treatment between dialysis sessions when indicated. [4], [8]
EXTRIP action | Trigger — any one sufficient | Practical clarification |
|---|---|---|
Recommended (1D) | Salicylate >100 mg/dL; >90 mg/dL with impaired kidney function; altered mental status; new hypoxemia requiring supplemental oxygen; or failure of standard therapy | Clinical findings can outweigh a lower concentration. |
Suggested (2D) | >90 mg/dL; >80 mg/dL with impaired kidney function; or systemic pH ≤7.20 | Chronic poisoning and comorbidity require individualized assessment. |
Cessation | Clinical improvement AND (salicylate <19 mg/dL OR ECTR for at least 4–6 hours if concentrations are unavailable) | Monitor rebound and continue bicarbonate between sessions when appropriate. |
The 2015 EXTRIP journal abstract describes ARDS requiring oxygen, whereas the detailed EXTRIP workgroup recommendation states new hypoxemia requiring supplemental oxygen.
The detailed workgroup wording is used here. Evaluate alternative causes of hypoxemia and the overall salicylate trajectory. [8], [23]
Preferred ECTR: Intermittent hemodialysis.
These thresholds prompt urgent nephrology and medical-toxicology evaluation; they do not replace assessment of the clinical trajectory.
Start fomepizole promptly for suspected clinically important methanol or ethylene glycol poisoning without waiting for confirmatory concentrations when the delay could increase risk.
Ethanol is an alternative when fomepizole is unavailable and suitable expertise and monitoring exist.
Severe poisoning may require intermittent hemodialysis.
Continue alcohol dehydrogenase blockade during extracorporeal treatment and account for antidote removal by dialysis.
U.S. fomepizole labeling specifies dosing every 4 hours during intermittent hemodialysis, with additional rules for dosing at the beginning and end of dialysis.
Do not use the standard off-dialysis fomepizole interval without adjustment.
Ethanol likewise requires dialysis-adjusted administration and frequent level monitoring.
Continuous kidney replacement therapy regimens require individualized pharmacy and toxicology input.
Folate or folinic acid may be used as an adjunct in methanol poisoning. [15], [16], [24]
ECTR recommended (1D) when any criterion is present | Cessation / modality |
|---|---|
Coma, seizures, new visual deficit, pH ≤7.15, persistent acidosis despite adequate treatment, conventional AG >24 mmol/L, or impaired kidney function. | Intermittent hemodialysis preferred. |
Methanol >70 mg/dL with fomepizole, >60 mg/dL with ethanol, or >50 mg/dL without an ADH blocker. | EXTRIP permits stopping when methanol is <20 mg/dL and clinical improvement is present. |
For methanol, calculate the anion gap as:
Na − Cl − HCO₃
When methanol concentration is unavailable, an ethanol-adjusted osmol gap may support assessment but is not independently diagnostic. [15]
For expanded clinical management, see Methanol Poisoning: Clinical Recognition, Triage, and Treatment.
ECTR recommendation | Trigger | Important context |
|---|---|---|
Recommended | Glycolate >12 mmol/L; or EXTRIP AG >27 mmol/L; or coma, seizures, or KDIGO stage 2–3 acute kidney injury | Requires evidence of ethylene glycol exposure for glycolate/AG criteria. |
Suggested | Glycolate 8–12 mmol/L; or EXTRIP AG 23–27 mmol/L | Consider clinical trajectory and assay availability. |
With fomepizole | Suggest ECTR if EG >50 mmol/L (>310 mg/dL) or ethanol-adjusted osmol gap >50 | Conditional on evidence of exposure and the antidote used. |
With ethanol | Recommend ECTR if EG >50 mmol/L or osmol gap >50; suggest ECTR if EG 20–50 mmol/L or osmol gap 20–50 | Use the full source-specific criteria. |
Without an ADH blocker | Recommend ECTR if EG >10 mmol/L (>62 mg/dL) or osmol gap >10 | Exposure history alone is not a dialysis criterion. |
Cessation | EXTRIP AG <18 mmol/L (recommended); EG <4 mmol/L (<25 mg/dL) or corrected acid–base status (suggested) | Reassess metabolites, treatment response, and rebound risk. |
For ethylene glycol, the EXTRIP anion-gap formula is:
Na + K − Cl − HCO₃
Clinically serious manifestations may justify dialysis independent of parent-compound concentrations.
Antidote-dependent concentration and osmol-gap thresholds must not be generalized across fomepizole, ethanol, and no-antidote states. [16]
Practice point: Isopropanol poisoning is managed primarily with supportive care.
Fomepizole is not routinely indicated for isolated isopropanol poisoning, because blocking its metabolism may prolong the parent compound's effects. [17]
Use the 2023 U.S.–Canada consensus rather than a one-size-fits-all nomogram.
For an acute ingestion with a reliable exposure time, interpret an appropriately timed concentration on the consensus nomogram.
Different pathways are required for:
Unknown ingestion time
Repeated supratherapeutic ingestion
High-risk dose
Altered absorption
Other nonstandard presentations
Begin N-acetylcysteine (NAC) when indicated, including before confirmatory levels if waiting would delay treatment beyond a safe window.
Do not stop NAC simply because 20 or 21 hours have elapsed.
Confirm consensus stopping criteria based on:
Acetaminophen concentration
Aminotransferases
INR
Clinical course
Discuss transplantation evaluation early in acute liver failure. [7]
Benzodiazepines are first-line treatment for most toxin-induced seizures and severe stimulant-related agitation.
Escalate refractory seizures to airway-supported anesthetic therapy and EEG monitoring when indicated.
Phenytoin is generally not preferred for toxin-induced seizures, especially when sodium-channel blockade may be involved.
Treat toxic hyperthermia by:
Prompt sedation
Active cooling
Reducing excessive muscular activity
Airway and ventilation support when necessary
Antipyretics do not treat the primary mechanism of toxic hyperthermia. [1], [25], [26]
Stop serotonergic agents.
Recognize clonus, hyperreflexia, agitation, diaphoresis, and hyperthermia.
Severe rigidity and hyperthermia require immediate resuscitation, benzodiazepines, aggressive cooling, and potentially intubation with nondepolarizing paralysis.
Cyproheptadine may be considered as an adjunct, but benefit for major clinical outcomes remains uncertain.
Do not delay cooling and supportive care to administer cyproheptadine.
Practice point: Avoid prolonged physical restraint of a struggling hyperthermic patient. [26]
Obtain an ECG, provide supportive care, and assess co-ingestants.
For well-characterized antimuscarinic delirium without QRS prolongation, physostigmine can be an effective antidote after individualized risk assessment, with:
Continuous monitoring
Airway support
Resuscitation capability
A 2019 review involving 2,299 patients found that important adverse effects were infrequently reported.
The review advised avoiding physostigmine in patients with QRS prolongation and exercising caution with coronary artery disease or QRS-prolonging co-ingestants.
Physostigmine is not a general antidote for coma. [27]
Prevent secondary contamination.
Prioritize:
Suctioning
Oxygenation
Ventilation
Management of bronchorrhea and respiratory failure
Titrate atropine to control respiratory secretions and improve oxygenation rather than to achieve a particular pupil size.
Consider pralidoxime for serious suspected organophosphate poisoning, recognizing differences in agent, time since exposure, and aging kinetics.
Monitor for respiratory muscle weakness and recurrent cholinergic manifestations. [1]
For strongly suspected life-threatening cyanide toxicity, promptly administer hydroxocobalamin.
AHA recommendation: COR 1, LOE C-LD in adults.
When hydroxocobalamin is unavailable, sodium nitrite plus sodium thiosulfate is the recommended alternative (COR 1, C-LD).
For simultaneous carbon monoxide and cyanide poisoning, such as a smoke-inhalation victim, sodium thiosulfate alone is reasonable if hydroxocobalamin is unavailable (COR 2a, C-EO).
Nitrite-induced methemoglobinemia can worsen oxygen delivery.
This alternative is supported by limited evidence, not comparative human trials.
Nitrite—not nitrate—is the correct drug name.
Notify laboratory and dialysis teams that hydroxocobalamin may interfere with colorimetric assays and falsely activate hemodialysis blood-leak detectors. [1]
Confirm with co-oximetry and support oxygenation.
Methylene blue may be indicated in clinically consequential methemoglobinemia.
Current U.S. labeling warns of serious or fatal serotonin syndrome when methylene blue is combined with serotonergic drugs, including SSRIs, SNRIs, MAO inhibitors, and certain opioids.
Methylene blue is contraindicated in G6PD deficiency under current U.S. labeling because of hemolysis risk and may be less effective.
Review medication history and deficiency risk.
Seek urgent medical-toxicology advice when treatment alternatives or life-saving decisions are difficult.
Monitor for rebound with agents such as dapsone.
Do not rely on conventional pulse oximetry alone. [1], [28]
Administer high-concentration (100%) oxygen for suspected clinically significant CO poisoning.
Confirm exposure with blood carboxyhemoglobin measured by laboratory co-oximetry.
Carboxyhemoglobin may decline after removal from exposure or administration of oxygen.
Conventional pulse oximetry cannot rule out CO poisoning.
Assess neurologic and cardiac injury, and consult hyperbaric or toxicology specialists for individualized decisions. [13]
Use digoxin immune Fab for life-threatening poisoning, important dysrhythmias, severe poisoning-associated hyperkalemia, or other severe findings, guided by current recommendations.
Correct associated metabolic abnormalities.
Monitor ECG and potassium.
Practice point: After Fab, most conventional total digoxin immunoassays may remain misleadingly elevated because they detect Fab-bound digoxin.
Assess treatment efficacy using clinical response, ECG, and potassium rather than uncorrected total digoxin concentrations.
IV calcium is not a substitute for Fab in digoxin-related hyperkalemia.
Avoid unsupported claims that all calcium administration is uniformly dangerous in every digoxin-exposed patient. [1], [12]
Correct hypoglycemia promptly with dextrose.
Then consider octreotide for sulfonylurea-associated hypoglycemia to limit recurrent insulin secretion.
Monitor for delayed and recurrent hypoglycemia. [29]
For detailed monitoring and disposition, see Sulfonylurea Poisoning: Recurrent Hypoglycemia, Dextrose, Octreotide, and Monitoring.
For suspected isoniazid-induced seizures, administer pyridoxine promptly with benzodiazepines, airway protection, and supportive care.
Use an exposure-specific antidote dosing protocol. [30]
Assess:
Acute, chronic, or acute-on-chronic exposure
Serial lithium concentrations
Renal function
Hydration
Neurologic manifestations
Co-ingestants
Consider isotonic fluids when appropriate.
Do not force diuresis.
Clinical status may matter more than a single concentration, especially in chronic toxicity.
EXTRIP recommends ECTR:
With impaired kidney function and lithium >4.0 mEq/L
With decreased consciousness, seizures, or life-threatening dysrhythmia regardless of concentration
Both are grade 1D recommendations.
EXTRIP suggests ECTR:
Lithium >5.0 mEq/L
Significant confusion
Expected time to lithium <1.0 mEq/L exceeding 36 hours
These are grade 2D recommendations.
Intermittent hemodialysis is preferred.
Check serial lithium levels for approximately 12 hours after ECTR to detect rebound and determine whether further treatment is needed. [9]
In a patient taking metformin, do not attribute every episode of lactic acidosis to metformin without evaluating:
Sepsis
Shock
Ischemia
Acute kidney injury
Other causes
For severe suspected metformin-associated or metformin-induced lactic acidosis, stabilize circulation and acid–base status and obtain early nephrology and medical-toxicology input.
EXTRIP recommends ECTR for:
Lactate >20 mmol/L
pH ≤7.0
Failure of standard supportive measures
These are grade 1D recommendations.
EXTRIP suggests ECTR for:
Lactate 15–20 mmol/L
pH in the approximately 7.0–7.1 range
These are grade 2D recommendations.
Importantly, the original EXTRIP abstract includes shock (1D) and decreased consciousness (2D) among clinical considerations for ECTR.
The detailed EXTRIP Table 8 classifies:
Clinical condition lowering the ECTR threshold | EXTRIP grade |
|---|---|
Shock | 1D |
Impaired kidney function | 1D |
Decreased consciousness | 2D |
Liver failure | 2D |
Do not require lactate >20 mmol/L before seeking urgent ECTR evaluation in severe suspected MALA with shock.
Conversely, do not initiate dialysis solely because a patient uses metformin or has nonspecific shock without considering acidemia, severity, trajectory, and alternative causes.
ECTR cessation requires both:
Lactate <3 mmol/L
pH >7.35
Monitor for rebound after treatment.
Intermittent hemodialysis is preferred when feasible.
Routine activated charcoal is not recommended for metformin under the 2026 CTRC guidance. [3], [31]
Monitor:
Serial valproate concentrations
Mental status
Ammonia
pH
Liver function
Cerebral-edema risk
Consider IV L-carnitine in selected severe valproate poisoning with hyperammonemia or hepatotoxicity after toxicology consultation.
Patient-oriented efficacy data and optimal dosing remain uncertain.
Gziut and Thanacoody propose a pharmacokinetically driven IV loading dose followed by continuous infusion rather than oral treatment or repeated IV boluses.
This proposed regimen has not been prospectively validated or established as standard dosing.
Use locally approved dosing and monitoring guidance. [32]
EXTRIP recommends ECTR for:
Valproate >1,300 mg/L
Shock
Cerebral edema
Grade 1D.
EXTRIP suggests ECTR for:
Valproate >900 mg/L
Coma or respiratory depression requiring mechanical ventilation
Acute hyperammonemia
pH <7.10
Grade 2D. [10]
Anticipate delayed and prolonged toxicity.
Monitor serial:
Carbamazepine concentrations
ECG
Neurologic status
Consider multiple-dose activated charcoal when bowel function and airway safety permit.
EXTRIP recommends ECTR for:
Refractory multiple seizures
Life-threatening dysrhythmias
ECTR is suggested for prolonged coma requiring ventilation or persistent severe toxicity despite MDAC and supportive care.
Continue MDAC during ECTR when appropriate. [3], [11]
Reversal is agent-specific.
Examples include:
Warfarin: Serious bleeding generally requires IV vitamin K and four-factor prothrombin complex concentrate.
Unfractionated heparin: Protamine.
Dabigatran: Idarucizumab.
For factor Xa inhibitors, use current local hematology guidance and balance bleeding control against thrombotic risk.
Important U.S. regulatory update: Andexxa ceased U.S. commercial sales on December 22, 2025, after an FDA risk assessment.
Older U.S. algorithms listing routine Andexxa availability are outdated. [33], [34]
Practice point: A known or suspected body packer with abrupt severe sympathomimetic toxicity (especially cocaine), opioid toxicity, or acute abdomen needs immediate resuscitation and urgent medical-toxicology and surgical assessment.
Support ventilation, circulation, and seizure treatment according to the presentation.
Suspected packet rupture or obstruction may require urgent surgical source control.
Symptomatic packet rupture is not managed by continuing whole-bowel irrigation alone. [19], [21]
Withdrawal syndromes are outside this Guideline's primary scope but may emerge during ICU care after mixed ingestion or prolonged hospitalization.
Manage withdrawal under separate syndrome-specific guidance.
Do not determine dialysis need based on molecular weight or protein binding alone.
EXTRIP criteria integrate:
Clinical severity
Antidote status
Concentrations
Laboratory trends
Organ dysfunction
The following thresholds are condensed poison-specific EXTRIP recommendations, not newly validated cutoffs. [8], [9], [10], [11], [15], [16], [23], [31]
For expanded substance-specific criteria, see Extracorporeal Treatment (Hemodialysis) in Poisoning — Clinical Guideline.
Exposure | Recommended ECTR triggers | Suggested triggers, monitoring, or stopping points |
|---|---|---|
Salicylates | >100 mg/dL; >90 mg/dL with impaired kidney function; altered mental status; new hypoxemia requiring supplemental oxygen; failure of standard therapy | Suggest at >90 mg/dL, >80 mg/dL with impaired kidney function, or pH ≤7.20. Stop with clinical improvement AND (<19 mg/dL OR ≥4–6 h ECTR if levels unavailable). |
Methanol | Coma, seizures, visual deficit, pH ≤7.15, refractory acidosis, conventional AG >24, impaired kidney function; levels >70/60/50 mg/dL with fomepizole/ethanol/no blocker | Continue ADH blockade with dialysis adjustment. Stop when methanol <20 mg/dL and clinical improvement is present. |
Ethylene glycol | With evidence of exposure: glycolate >12 mmol/L; K-included AG >27; coma, seizures, KDIGO stage 2–3 AKI. With ethanol: EG >50 mmol/L or osmol gap >50; without ADH blocker: EG >10 mmol/L or osmol gap >10 | Suggest for glycolate 8–12, K-included AG 23–27; with fomepizole, EG >50 mmol/L or osmol gap >50; with ethanol, EG 20–50 or osmol gap 20–50. Stop with K-included AG <18 or another specified endpoint. |
Lithium | Impaired kidney function with lithium >4.0 mEq/L; decreased consciousness, seizures, or life-threatening dysrhythmia irrespective of level | Suggest at >5.0 mEq/L, confusion, or expected >36 h to <1.0. Check rebound for approximately 12 h. |
Metformin | Lactate >20 mmol/L, pH ≤7.0, or failure of supportive measures. Severe suspected MALA with shock warrants urgent ECTR assessment, potentially at lower lactate values | Suggest lactate 15–20 or pH around 7.0–7.1. Shock/renal impairment (1D) and decreased consciousness/liver failure (2D) lower initiation threshold. Stop only when lactate <3 AND pH >7.35. |
Valproate | >1,300 mg/L, shock, or cerebral edema | Suggest >900 mg/L, coma requiring ventilation, acute hyperammonemia, or pH <7.10. |
Carbamazepine | Refractory multiple seizures or life-threatening dysrhythmia | Suggest for prolonged coma/ventilation or persistent severe toxicity despite MDAC/support. |
Important formula distinction
For methanol, use the potassium-excluded anion gap:
Na − Cl − HCO₃
For ethylene glycol, use the potassium-included anion gap:
Na + K − Cl − HCO₃
Ethylene glycol concentration/osmol-gap recommendations depend on fomepizole, ethanol, or no ADH blocker.
Do not generalize the thresholds across those circumstances.
When precise concentrations are unavailable, clinical deterioration and acidemia may be decisive. [15], [16]
ICU-level care is indicated or strongly considered for:
Respiratory failure
Hemodynamic instability
Recurrent seizures
Malignant dysrhythmias or conduction abnormalities
Severe metabolic derangements
Major organ injury
Risk of delayed decompensation
Therapies requiring high-acuity monitoring and adjustment, including escalating vasopressors, HIET, ECMO, or selected ECTR
Practice point: A stable patient receiving routine NAC alone does not automatically require ICU admission.
The trajectory, patient factors, and local monitoring capabilities determine the appropriate level of care. [2]
Reassess and document:
Airway and ventilation
Mental status
Serial ECG, QRS, and QTc
Perfusion
Vasoactive-drug requirements
Glucose and potassium during HIET
Acid–base status and urine pH during bicarbonate treatment
Relevant serial toxicant concentrations
Kidney and liver function
Fluid balance
Treatment-related adverse effects
Use poison-specific endpoints for antidotes, dialysis, and observation. [1], [4], [7], [8], [15], [16]
De-escalate only after:
Sustained physiologic stability
Completion of an appropriate toxin- and formulation-specific observation period
No ongoing high-acuity therapy
Resolution of dangerous clinical or laboratory trends
A clear follow-up and psychiatric safety plan when relevant
There is no universal ICU or ED observation period for all poisonings.
Practice point — ungraded. [2]
Presentation | Immediate priority | Targeted next action or caution |
|---|---|---|
Hypoventilating coma | Assisted ventilation, glucose, ECG | Titrate naloxone if opioid involvement is likely; avoid empirical flumazenil. |
Widened QRS with shock | Resuscitation, serial ECG | If sodium-channel blockade, give bicarbonate; monitor pH, sodium, and potassium. |
CCB/BB shock | Perfusion, vasopressors, echocardiography | HIET by protocol; calcium for CCB; selective glucagon for BB; early ECMO referral. |
Salicylates with acidemia or neurologic change | Preserve compensatory respiratory alkalosis; bicarbonate | Apply EXTRIP criteria urgently; intubation presents particular risk. |
High-anion-gap acidosis with possible toxic alcohol | Targeted assays, pH, AG formula review | Start fomepizole if clinically suspected; assess ECTR criteria. |
High osmol gap and ketosis without prominent acidosis | Glucose, ketones, ethanol, acid–base status, history | Consider isopropanol and other causes; supportive treatment usually; fomepizole not routine for isolated isopropanol. [17] |
Severe metformin-associated lactic acidosis | Shock management, alternative-cause evaluation | Apply lactate, pH, and clinical EXTRIP criteria. |
Severe lithium or valproate neurotoxicity | Serial levels, neurologic and renal review | Apply substance-specific ECTR guidance. |
Hyperthermia with rigidity or clonus | Sedation, active cooling, airway preparation | Treat severe serotonin toxicity supportively; do not wait for cyproheptadine. |
Suspected body-packer packet rupture | Resuscitate and treat stimulant/opioid toxicity and seizures; ECG monitoring | Immediate medical-toxicology and surgical consultation; source control may be necessary. [19], [21] |
Antimuscarinic delirium | ECG, hydration, supportive care | Consider monitored physostigmine only with appropriate selection and without QRS prolongation. |
Cholinergic pulmonary secretions | PPE, suction, airway, oxygenation | Titrate atropine to respiratory secretion control; consider an oxime for organophosphates. |
Smoke inhalation with suspected cyanide | Oxygen, resuscitation | Hydroxocobalamin; if unavailable with concurrent CO exposure, thiosulfate alone may be reasonable. |
Methemoglobinemia | Co-oximetry, oxygen | Review G6PD deficiency and serotonergic medications before methylene blue. |
Recurrent sulfonylurea hypoglycemia | Dextrose, glucose surveillance | Octreotide and appropriate observation. |
Source note: This table is a condensed quick-action reference, not a collection of stand-alone protocols. Consult the detailed treatment sections and original guidance for dosing, contraindications, and monitoring. [1], [3], [8], [9], [10], [11], [15], [16], [22], [23], [25], [26], [27], [28], [29], [31]
The source manuscript reports source-to-claim reconciliation completed on November 13, 2026, including the original EXTRIP publications and detailed salicylate workgroup recommendations.
Additional primary or official sources were reviewed for:
Carbon monoxide
Sulfonylurea-induced hypoglycemia
Isoniazid seizures
Toxic seizures
Thiamine-related risk
General poisoned-patient assessment
This is narrative clinical guidance, not a systematic review or an institutional order set.
AHA grading, EXTRIP grades, and CTRC ratings belong to their respective recommendations and must not be treated as interchangeable.
EXTRIP 1D recommendations may reflect strong expert agreement despite very-low-quality clinical evidence.
No new numerical efficacy claims, outcome estimates, or universal dosing regimens have been inferred from those grades.
This review relies on:
The 2025 AHA special-circumstances guideline
The 2026 CTRC activated-charcoal recommendations
The 2015 AACT/EAPCCT whole-bowel-irrigation position paper
Substance-specific EXTRIP publications
The 2023 North American acetaminophen consensus
Current FDA safety communications and product labeling
The peer-reviewed reviews listed below
Drug availability, dosing, and contraindications may change.
Verify current product labeling and institutional protocols before acting on any medication-specific recommendation.
Keep reading